No Data
CRMI (08158.HK) signed a leasing agreement with Positron.
Grace Covenant, November 1st - China Regenerative Medicine (08158.HK) announced that on November 1, 2024, the company's wholly owned subsidiary HKIRC and CRMI (Hong Kong) (as tenant) entered into a lease agreement with independent third party Zhengxin (as landlord), accordingly, Zhengxin agreed to lease the property to the company.
CRMI: Interim Report 2024
crmi (08158) announced its interim results with a net profit of 16.828 million Hong Kong dollars, a year-on-year increase of 31.86%.
CRMI (08158) announced its mid-term performance for 2024, with earnings of 59.785 million Hong Kong dollars, a year-on-year decrease...
Express News | China Regenerative Medicine International H1 Gross Profit HKD 39.49 Million
Express News | China Regenerative Medicine International H1 Operating Expenses HKD 22.11 Million
Express News | China Regenerative Medicine International H1 Revenue HKD 59.78 Million
Little Excitement Around China Regenerative Medicine International Limited's (HKG:8158) Revenues As Shares Take 25% Pounding
No Data
